China biotech taps Big Data as next weapon against cancer

Hong Kong

WHEN Nisa Leung was pregnant with her first child in 2012, her doctor in Hong Kong offered her a choice. She could take a prenatal test that would require inserting a needle into her uterus, or pay US$130 more for an exam that would draw a little blood from her arm.

Ms Leung opted for the simpler and less risky test, which analysed bits of the baby's DNA that had made its way into her bloodstream. Then, Ms Leung went on to do what she often does when she recognises a good product: look around for companies to invest in.